

Robert R Henry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4703703/publications.pdf>

Version: 2024-02-01

50
papers

6,118
citations

117453

34
h-index

189595

50
g-index

55
all docs

55
docs citations

55
times ranked

8303
citing authors

#	ARTICLE	IF	CITATIONS
1	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	18.1	1,308
2	Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence, 2016, Volume 10, 1299-1307.	0.8	448
3	American Association of Clinical Endocrinologists and American College of Endocrinology "Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan " 2015 " Executive Summary. Endocrine Practice, 2015, 21, 413-437.	1.1	359
4	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. New England Journal of Medicine, 2017, 377, 2337-2348.	13.9	322
5	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium"Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
6	Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier. Molecular Cell, 2014, 56, 425-435.	4.5	243
7	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocrine Practice, 2016, 22, 753-762.	1.1	242
8	Efficacy and Safety of Canagliflozin, a Sodium"Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, 2258-2265.	4.3	235
9	Effect of Aloglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
10	Effect of the dual peroxisome proliferator-activated receptor- α/β agonist aloglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet, The, 2009, 374, 126-135.	6.3	196
11	Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Diabetes Care, 2015, 38, 412-419.	4.3	191
12	Sodium"Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport. Diabetes Care, 2015, 38, 2344-2353.	4.3	186
13	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. European Heart Journal, 2016, 37, 2981-2989.	1.0	142
14	Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R441-R447.	0.9	134
15	Benefits and Limitations of Very-Low-Calorie Diet Therapy in Obese NIDDM. Diabetes Care, 1991, 14, 802-823.	4.3	125
16	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 812-821.	2.2	117
17	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM"NSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
18	Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor- β 1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2830-2835.	1.8	89

#	ARTICLE	IF	CITATIONS
19	(âˆ™)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. <i>International Journal of Cardiology</i> , 2013, 168, 3982-3990.	0.8	83
20	Diabetic Ketoacidosis With Canagliflozin, a Sodiumâ€“Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 532-538.	4.3	83
21	Alirocumab vs usual lipidâ€“lowering care as addâ€“on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€“DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
22	Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 393-398.	1.2	71
23	SGLT inhibitor adjunct therapy in type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 2126-2133.	2.9	68
24	Can a Selective PPARÎ³ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?. <i>Diabetes Care</i> , 2014, 37, 1918-1923.	4.3	61
25	Impaired Muscle Glycogen Synthase in Type 2 Diabetes Is Associated with Diminished Phosphatidylinositol 3-Kinase Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4307-4314.	1.8	56
26	Glucosamine Regulation of Glucose Metabolism in Cultured Human Skeletal Muscle Cells: Divergent Effects on Glucose Transport/Phosphorylation and Glycogen Synthase in Non-Diabetic and Type 2 Diabetic Subjects. <i>Endocrinology</i> , 1999, 140, 3971-3980.	1.4	51
27	Effect of a glucagon receptor antibody (REMDâ€“477) in type 1 diabetes: A randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1302-1305.	2.2	50
28	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2108-2116.	4.3	50
29	Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 715-724.	2.4	49
30	Effects of Tumor Necrosis Factor-Î± on Glucose Metabolism in Cultured Human Muscle Cells from Nondiabetic and Type 2 Diabetic Subjects. <i>Endocrinology</i> , 1998, 139, 4793-4800.	1.4	44
31	Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. <i>Endocrine Practice</i> , 2011, 17, 906-913.	1.1	44
32	Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2559-2565.	4.3	43
33	Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1189-1196.	4.3	41
34	Evaluation of the dual peroxisome proliferatorâ€“activated receptor Î±/Î³ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	1.2	39
35	Dapagliflozin in patients with type 1 diabetes: <i>post hoc</i> analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting Î²-hydroxybutyrate levels in a phase IIa pilot study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 814-821.	2.2	34
36	Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle. <i>Journal of Biological Chemistry</i> , 2017, 292, 12339-12350.	1.6	28

#	ARTICLE	IF	CITATIONS
37	A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes†††This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited. <i>Clinical Therapeutics</i> , 2013, 35, 634-645.†	1.1	26
38	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	2.7	25
39	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. <i>Diabetes Care</i> , 2018, 41, 613-619.	4.3	25
40	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , 2018, 41, 1792-1800.	4.3	25
41	Circulating ApoJ is closely associated with insulin resistance in human subjects. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 155-166.	1.5	24
42	Early Alteration in Glomerular Reserve in Humans at Genetic Risk of Essential Hypertension. <i>Hypertension</i> , 2001, 37, 898-906.	1.3	23
43	Reduced Glucose-Induced Thermogenesis Is Present in Noninsulin-Dependent Diabetes Mellitus without Obesity*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 801-807.	1.8	16
44	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1632-1641.	2.2	15
45	Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. <i>Age</i> , 2016, 38, 485-493.	3.0	10
46	PPAR Î³ Agonists and the Future for Insulin Sensitizers. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 206-210.	0.6	6
47	Treatment satisfaction with ITCA 650, a novel drugâ€device delivering continuous exenatide, versus twiceâ€daily injections of exenatide in type 2 diabetics using metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 638-645.	2.2	6
48	Strategies for preventing type II diabetes. <i>Postgraduate Medicine</i> , 1997, 101, 181-189.	0.9	5
49	p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. <i>JCI Insight</i> , 2022, 7, .	2.3	3
50	Effects of epicatechin rich cocoa on REDUX status in human skeletal muscle. <i>FASEB Journal</i> , 2012, 26, 888.11.	0.2	2